gdc
Neuroendocrine Tumors

Lutathera First Radioactive Drug Approved for Gastroenteropancreatic NETs

May 2018 – Cancer Biomarkers and Molecular Testing

On January 26, 2018, the FDA approved Lutathera (lutetium Lu 177 dotatate; from Advanced Accelerator Applications), a radioactive drug, for the treatment of adults with somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This is the first approval of a radioactive drug for the treatment of patients with GEP-NETs.

“GEP-NETs are a rare group of cancers with limited treatment options after initial therapy fails to keep the cancer from growing.

This approval provides another treatment choice for patients with these rare cancers,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence. This approval was based on the results of 2 clinical trials. In the first study, patients who received Lutathera plus Sandostatin LAR (octreotide) had longer time without disease progression than those who received Sandostatin LAR alone. This resulted in lower death risk and less tumor growth in those who received the combination therapy. In the second study, almost one-quarter of the patients with GEP-NETs responded to therapy with Lutathera

The common side effects with Lutathera include lymphopenia, vomiting, nausea, hyperglycemia, and hypokalemia. Patients should know that they are being exposed to radiation, which may cause harm to a fetus.

Share this:

Recommended For You
Neuroendocrine Tumors
Drugs for NETs/Carcinoid Syndrome
Here are the drugs and financial support services available to patients receiving treatment for Neuroendocrine Tumors (NETs)/Carcinoid Syndrome.
Legal CornerNeuroendocrine Tumors
Tackling the Impossible: Greta Stifel Is Making History for Patients with Rare Cancers
By Yvette Florio Lane
One woman’s personal battle with a rare cancer was the motivation to change the law regulating the way doctors are educated in her state. Will your state be next? Read more about Greta Stifel’s journey from patient to lawmaker.
CONQUER CamNeuroendocrine TumorsPatient Stories
CONQUER Cam: A Spotlight on Cindy Lovelace
Cindy Lovelace shares her extraordinary cancer journey, being a survivor of not one, but two different types of cancer – breast cancer and neuroendocrine tumor (NET) cancer. Listen to Cindy’s story as she talks about her diagnoses and courses of treatment, and delves deeper into going through a clinical trial, which dictated her treatment path for NET.
Neuroendocrine TumorsPatient StoriesSurvivorship
Power to the Butterfly: Thriving After a Neuroendocrine Tumor Diagnosis
By Greta Stifel
Read about Greta Stifel’s battle with a NET diagnosis and her mission to spread awareness of NETs and empower others dealing with this rare, often misdiagnosed cancer type.
Last modified: June 28, 2018

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country